Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that the U.S. Patent and Trademark Office has issued a new patent covering its lead investigational therapy, istaroxime, for intravenous treatment …
Windtree Therapeutics Secures U.S. Patent for Istaroxime Heart Failure Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has achieved a major milestone in its Phase 2 SEISMiC C study, announcing the planned enrollment of 20 patients for its interim …
Windtree Therapeutics Advances Istaroxime Phase 2 Study with Interim Analysis Enrollment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the publication of findings from its Phase 2 SEISMiC B study on istaroxime in the Journal of Heart and Lung …
Windtree Therapeutics Announces Promising Phase 2 Study Results for Istaroxime Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT), announced that it has received a non-binding letter of intent to sell its preclinical oncology aPKCi inhibitor platform for $7 million in …
Windtree Therapeutics Receives $7 Million Offer for Preclinical Oncology Platform Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced a strategic acquisition of Titan Environmental Services, Inc. (OTC: TESI), marking a significant step in its shift toward profitability and entry …
Windtree Therapeutics Acquires Titan Environmental Services to Drive Profitability Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has revealed plans to adopt a cryptocurrency policy, marking a significant step toward integrating digital finance into its operations. The policy will …
Windtree Therapeutics Announces Move into Cryptocurrency Payments and Holdings Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced its plan to release interim data from the SEISMiC SCAI Stage C Phase 2 study (SEISMiC C Study) by July …
Windtree Therapeutics Targets July for Interim Data from Key Cardiogenic Shock Study Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has unveiled new data on istaroxime, a treatment candidate for cardiogenic shock, at the European Society of Cardiology Heart Failure 2025 Conference …
Windtree Showcases Promising Istaroxime Data for Cardiogenic Shock at Major Conference Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced its first-quarter 2025 financial results and shared updates on its strategy to evolve into a revenue-generating company while advancing its …
Windtree Therapeutics Reports Q1 2025 Financial Results and Strategic Milestones Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced its strategy to secure 7.5 years of U.S. exclusivity for istaroxime, its investigational treatment for cardiogenic shock, if approved by the …
Windtree Therapeutics Unveils U.S. Exclusivity Strategy for Istaroxime Read More